AU2021276656A1 - Deuterated tryptamine derivatives and methods of use - Google Patents

Deuterated tryptamine derivatives and methods of use Download PDF

Info

Publication number
AU2021276656A1
AU2021276656A1 AU2021276656A AU2021276656A AU2021276656A1 AU 2021276656 A1 AU2021276656 A1 AU 2021276656A1 AU 2021276656 A AU2021276656 A AU 2021276656A AU 2021276656 A AU2021276656 A AU 2021276656A AU 2021276656 A1 AU2021276656 A1 AU 2021276656A1
Authority
AU
Australia
Prior art keywords
unsubstituted
substituted
hydrogen
deuterium
partially
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021276656A
Other languages
English (en)
Inventor
Alex Nivorozhkin
Michael Palfreyman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cybin IRL Ltd
Original Assignee
Cybin IRL Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cybin IRL Ltd filed Critical Cybin IRL Ltd
Priority claimed from PCT/IB2021/054340 external-priority patent/WO2021234608A1/en
Publication of AU2021276656A1 publication Critical patent/AU2021276656A1/en
Priority to AU2024203974A priority Critical patent/AU2024203974A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
AU2021276656A 2020-05-19 2021-05-19 Deuterated tryptamine derivatives and methods of use Pending AU2021276656A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024203974A AU2024203974A1 (en) 2020-05-19 2024-06-12 Deuterated tryptamine derivatives and methods of use

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063026939P 2020-05-19 2020-05-19
US63/026,939 2020-05-19
US202063114738P 2020-11-17 2020-11-17
US63/114,738 2020-11-17
US202163157118P 2021-03-05 2021-03-05
US63/157,118 2021-03-05
PCT/IB2021/054340 WO2021234608A1 (en) 2020-05-19 2021-05-19 Deuterated tryptamine derivatives and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024203974A Division AU2024203974A1 (en) 2020-05-19 2024-06-12 Deuterated tryptamine derivatives and methods of use

Publications (1)

Publication Number Publication Date
AU2021276656A1 true AU2021276656A1 (en) 2022-11-24

Family

ID=78608612

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2021276656A Pending AU2021276656A1 (en) 2020-05-19 2021-05-19 Deuterated tryptamine derivatives and methods of use
AU2024203974A Pending AU2024203974A1 (en) 2020-05-19 2024-06-12 Deuterated tryptamine derivatives and methods of use

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024203974A Pending AU2024203974A1 (en) 2020-05-19 2024-06-12 Deuterated tryptamine derivatives and methods of use

Country Status (11)

Country Link
US (12) US12240813B2 (https=)
EP (2) EP4153564A4 (https=)
JP (4) JP7766623B2 (https=)
KR (2) KR20240096817A (https=)
CN (2) CN118754841A (https=)
AU (2) AU2021276656A1 (https=)
CA (1) CA3177454A1 (https=)
CO (1) CO2022016662A2 (https=)
IL (3) IL297492A (https=)
MX (1) MX2022014605A (https=)
PH (1) PH12022553135A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
CN114787363A (zh) 2019-10-01 2022-07-22 恩派瑞安神经科学公司 对真菌进行遗传工程化以调节色胺表达
JP7422473B2 (ja) 2019-11-07 2024-01-26 サイビン ユーケー リミテッド 合成方法
PH12022551981A1 (en) 2020-02-04 2023-10-16 Mindset Pharma Inc Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
MX2022009528A (es) 2020-02-04 2022-11-14 Mindset Pharma Inc Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc.
AU2021268204A1 (en) 2020-05-08 2022-12-08 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
KR20240096817A (ko) 2020-05-19 2024-06-26 사이빈 아이알엘 리미티드 중수소화된 트립타민 유도체 및 사용 방법
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
US11773062B2 (en) * 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
US11324762B2 (en) 2020-10-08 2022-05-10 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof
US12521370B2 (en) 2020-12-01 2026-01-13 Cybin Uk Ltd Inhalable formulations
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
AU2022229037A1 (en) * 2021-03-02 2023-09-28 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
WO2022235500A1 (en) * 2021-05-03 2022-11-10 Mind Medicine, Inc. Psychedelics for treatment of pain
IL308816A (en) 2021-05-25 2024-01-01 Atai Therapeutics Inc New n,n-dimethyltryptamine salts and crystalline salt forms
MX2023014620A (es) 2021-06-09 2024-01-30 Atai Therapeutics Inc Nuevos profarmacos y conjugados de dimetiltriptamina.
US11344564B1 (en) 2021-08-20 2022-05-31 Lennham Pharmaceuticals, Inc. Method of treatment based on reduced monoamine oxidase a activity
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
US12318477B2 (en) 2021-11-18 2025-06-03 Cybin Uk Ltd Injectable and inhalable formulations
JP2024545787A (ja) 2021-12-30 2024-12-11 アタイ セラピューティクス， インコーポレイテッド 一酸化窒素送達剤としてのジメチルトリプタミン類似体
EP4457336A4 (en) 2021-12-31 2026-01-14 Empyrean Neuroscience Inc ORGANISMS GENETICALLY MODIFIED TO PRODUCE PSYCHOTROPIC ALKALOIDS
US20250051279A1 (en) * 2022-01-14 2025-02-13 Cybin Irl Limited Tryptamine compositions and methods
KR20250053871A (ko) * 2022-08-31 2025-04-22 사이빈 아이알엘 리미티드 트립타민 화합물, 조성물, 및 사용 방법
CN120344243A (zh) 2022-10-13 2025-07-18 赛本英国有限公司 包含致幻剂的胃肠外制剂的施用方法
EP4618981A1 (en) 2022-11-17 2025-09-24 Remedi, Inc. Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use
WO2024156713A1 (en) 2023-01-23 2024-08-02 Cybin Uk Ltd Treatment of psychiatric or neurological disorders by parenteral administration of a single, effective parenteral dose of a short-acting psychedelic agent
AU2024242138A1 (en) * 2023-03-31 2025-11-13 Cybin Uk Ltd Combination comprising a monoamine antidepressant agent and a short-duration psychedelic agent
EP4704806A1 (en) * 2023-05-05 2026-03-11 Cybin IRL Limited Injectable pharmaceutical formulations
CN121752545A (zh) * 2023-11-06 2026-03-27 宜昌人福药业有限责任公司 一种n,n-二甲基色胺衍生物及其药物组合物、制备方法和用途

Family Cites Families (389)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE265636C (https=)
CA672478A (en) 1963-10-15 Heim Roger Psilocybin and psilocin
DE255749C (https=)
GB672478A (en) 1949-07-22 1952-05-21 Atlas Diesel Ab Method and means for connecting drill rods, drill steels or drill bits for rock drilling
GB911946A (en) 1958-02-21 1962-12-05 Sandoz Ltd Psilocybin and psilocin and processes for their preparation
GB912715A (en) 1958-02-21 1962-12-12 Sandoz Ltd 4-hydroxytryptamines
US3072530A (en) 1958-09-12 1963-01-08 Sandoz Ag Therapeutic indoles for psychic stimulation and relief of mental depression
US3078214A (en) 1958-09-12 1963-02-19 Sandoz Ag Treatment of mental disturbances with esters of indoles
NL243249A (https=) 1958-09-12
FI34529A (fi) 1959-01-28 1964-10-10 Sandoz Ag Förfarande att i rent tillstånd tillvarataga de psykotropiskt verksamma föreningarna psilocybin och psilocin ur svamparter
US3192111A (en) 1959-02-16 1965-06-29 Sandoz Ltd Method of inducing therapeutic tranquilization with psilocybin and psilocin
GB981192A (en) 1960-03-30 1965-01-20 Westminster Bank Ltd Improvements in or relating to 4 hydroxytryptamine esters
GB982738A (en) 1961-06-05 1965-02-10 Ici Ltd 3-aminoalkylindoles
US3444174A (en) 1966-10-05 1969-05-13 American Cyanamid Co Substituted 4,7-dihydroindoles
US3583972A (en) 1969-06-11 1971-06-08 Upjohn Co N-dealkylation of cyclic tertiary amines
US3686213A (en) 1970-08-28 1972-08-22 American Cyanamid Co Substituted aminoethyl indoles
JPS55105664A (en) 1979-02-08 1980-08-13 Kawaken Fine Chem Co Ltd Preparation of tryptamine
US4855325A (en) 1985-01-16 1989-08-08 Naftchi Nosrat E Treatment of mammals suffering from damage to the central nervous system
EP0152379A3 (de) 1984-02-15 1986-10-29 Ciba-Geigy Ag Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend unilamellare Liposomen
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US6107499A (en) 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
WO1991001756A1 (en) 1989-08-11 1991-02-21 Skolnick Malcolm H Method for chemical promotion of the effects of low current transcranial electrostimulation
US5258379A (en) 1990-05-04 1993-11-02 Eli Lilly And Company Method of inhibiting gastric acid secretion with n-arylpiperazines
US5158956A (en) 1990-05-04 1992-10-27 Eli Lilly And Company Method of inhibiting gastric acid secretion with benzodioxanes
US5340838A (en) 1990-05-04 1994-08-23 Eli Lilly And Company Method of inhibiting gastric acid secretion with 2-phenylcyclopropylamines
CS276073B6 (cs) 1990-08-14 1992-03-18 Mikrobiologicky Ustav Csav Způsob přípravy biomasy s obsahem psilocybinu a peilociau ze etopkovýtrusá houby
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
FR2707639B1 (fr) 1993-06-30 1995-10-13 Pf Medicament Nouveaux composés indoliques dérivés d'arylamines comme ligands sélectifs des récepteurs 5HT1D et 5HT1B.
US5417987A (en) 1993-09-16 1995-05-23 Board Of Supervisors Of Louisiana State University Method for controlling bivalves such as zebra mussels
JPH0827029A (ja) 1994-07-19 1996-01-30 Fujisawa Pharmaceut Co Ltd ５ｈｔ１ 作動薬の新規医薬用途
JPH0827020A (ja) 1994-07-19 1996-01-30 Mitsubishi Chem Corp 破骨細胞形成促進及び骨吸収剤
US6207396B1 (en) 1995-11-20 2001-03-27 Microgenics Corporation Immunoassay reagents and methods for determination of LSD and LSD metabolites
EP0992511B1 (en) 1996-01-23 2009-03-11 Operon Biotechnologies, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
DE69739304D1 (de) 1996-01-23 2009-04-23 Operon Biotechnologies Inc Verfahren und Zusammensetzungen zur Bestimmung von Sequenzen von Nukleinsäure-Molekülen
US6027890A (en) 1996-01-23 2000-02-22 Rapigene, Inc. Methods and compositions for enhancing sensitivity in the analysis of biological-based assays
EP0962464A3 (en) 1996-01-23 2004-02-11 Qiagen Genomics, Inc. Methods and compositions for detecting binding of ligand pair using non-fluorescent label
HUP9900459A3 (en) 1996-01-23 1999-11-29 Rapigene Inc Bothell Methods and compositions for detecting binding of ligand pair using non-fluorescent label
US6312893B1 (en) 1996-01-23 2001-11-06 Qiagen Genomics, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
US6613508B1 (en) 1996-01-23 2003-09-02 Qiagen Genomics, Inc. Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques
FR2744361B1 (fr) 1996-02-07 1998-02-27 Rhone Poulenc Rorer Sa Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
AU738237B2 (en) 1997-07-22 2001-09-13 Qiagen Genomics, Inc. Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques
WO1999042840A1 (en) 1998-02-20 1999-08-26 Microgenics Corporation Immunoassays for determination of lsd and lsd metabolites
WO1998026644A2 (en) 1998-03-27 1998-06-25 Microgenics Corporation Confirmatory assays for small molecule drugs
US6306616B1 (en) 1998-03-27 2001-10-23 Microgenics Corporation Adsorption type confirmatory assays
AU3230299A (en) 1998-05-29 1999-12-09 Armacel Pty Limited An anchor mounting and installation method
WO2000003679A2 (en) 1998-07-14 2000-01-27 Adams Food Ltd. Nutritionally active composition for hardening fingernails
AU5243999A (en) 1998-07-31 2000-02-21 Vela Pharmaceuticals Inc. Methods and compositions for treating and preventing substance abuse using moclobemide
US6376531B1 (en) 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
US20010008641A1 (en) 1998-11-25 2001-07-19 R. Douglas Krotzer Nutritionally active composition for bodybuilding
US6403808B1 (en) 1999-12-10 2002-06-11 Virginia Commonwealth University Selective 5-HT6 receptor ligands
EP1693366A1 (en) 1998-12-11 2006-08-23 Virginia Commonwealth University Selective 5-HT 6 receptor ligands
DK1149078T3 (da) 1998-12-11 2006-07-10 Univ Virginia Commonwealth Selektive 5-HT6-receptorligander
AU2001225664A1 (en) 2000-06-15 2001-12-24 Respiratorius Ab 5-ht3 receptor antagonists for treatment of disorders involving airway constriction
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
CA2416650C (en) 2000-07-19 2010-09-21 Pitmy International N.V. Enhancement of the action of central and peripheral nervous system agents
AU2001291114A1 (en) 2000-09-19 2002-04-02 Microbia, Inc. Modulation of secondary metabolite production by zinc binuclear cluster proteins
AU2002211176A1 (en) 2000-11-01 2002-05-15 Respiratorius Ab Composition comprising serotonin receptor antagonists, 5 ht-2 and 5 ht-3
WO2002036113A1 (en) 2000-11-01 2002-05-10 Respiratorius Ab Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
US20030096013A1 (en) 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
DE60222396T2 (de) 2001-03-29 2008-05-15 Eli Lilly And Co., Indianapolis N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
US7132287B2 (en) 2001-06-18 2006-11-07 Psychiatric Genomics, Inc. Method for neural stem cell differentiation using 5HT-1A agonists
ITRM20010356A1 (it) 2001-06-21 2002-12-23 Sigma Tau Ind Farmaceuti "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
US20030007961A1 (en) 2001-06-22 2003-01-09 Wilburn Michael D. Orthomolecular vitamin E derivatives
US20030078231A1 (en) 2001-06-22 2003-04-24 Wilburn Michael D. Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties
AT501069A1 (de) 2001-08-20 2006-06-15 Walter Ing Pils Vorrichtung und verfahren zum nachweis eines analyten
WO2003016903A2 (de) 2001-08-20 2003-02-27 Walter Pils Vorrichtung und verfahren zum nachweis eines analyten
EP1321466B1 (en) 2001-12-20 2011-01-26 Randox Laboratories Ltd. Haptens, immunogens, antibodies and conjugates for 2-oxo-3-hydroxy LSD
US20040258617A1 (en) 2002-06-17 2004-12-23 Pearl Technology Holdings, Llc. Physical, chemical, and isotopic (atomic) labels
AU2003249584B9 (en) 2002-06-21 2008-05-15 Suven Life Sciences Limited Arylalkyl indoles having sertonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
BR0312176A (pt) 2002-06-21 2005-04-05 Suven Life Sciences Ltd Composto, composição farmaceutica, uso de um composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso, processo para a preparação de um composto, novo intermediario e processo para a preparação de um novo intermediario
US10738268B2 (en) 2016-08-21 2020-08-11 Insectergy, Llc Cannabis nanoemulsion methods
US11180781B2 (en) 2016-08-21 2021-11-23 Insectergy, Llc Biosynthetic cannabinoid production methods
EP2351770A1 (en) 2002-07-17 2011-08-03 Cytos Biotechnology AG Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
NZ537003A (en) 2002-07-18 2008-03-28 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
CA2498043A1 (en) 2002-08-05 2004-07-01 Baxter International Inc. Preparation of submicron sized particles with polymorph control and new polymorph of itraconazole
CN1688288A (zh) 2002-08-05 2005-10-26 巴克斯特国际公司 具有多晶型控制的亚微米粒度颗粒的制备和新多晶型伊曲康唑
AU2003278832A1 (en) 2002-09-13 2004-04-30 Carnegie Mellon University Optical biosensors and methods of use thereof
AU2003273977B2 (en) 2002-10-11 2007-07-12 Idea Ag Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
US20040105881A1 (en) 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
AU2003304211A1 (en) 2002-10-30 2005-01-04 The Regents Of The University Of California Direct micro-patterning of lipid bilayers using uv light and selected uses thereof
JP4174016B2 (ja) 2003-07-11 2008-10-29 株式会社ビーエル 競合法によるサイロシン類のイムノクロマトグラフィー検出法及びテストキット
JP4641942B2 (ja) 2003-10-03 2011-03-02 フェーイレン・ナムローゼ・フェンノートシャップ ヒトおよび動物におけるｉｇｆ−１血清レベルの低下と関連した種々の疾患状態の治療用の治療用組成物の製造のための血清中ｉｇｆ−１レベルを増加できる化合物の使用
US20050288616A1 (en) 2004-06-28 2005-12-29 Smiths Detection, Inc. Sampling swab
US7783333B2 (en) 2004-07-13 2010-08-24 Dexcom, Inc. Transcutaneous medical device with variable stiffness
AU2005300045A1 (en) 2004-09-27 2006-05-04 Organix, Inc. Indole compounds useful as serotonin selective agents
PL1844189T3 (pl) 2005-01-10 2021-10-25 Smiths Detection Inc. Sposób przygotowania wymazówki
DE102005008312A1 (de) 2005-02-17 2006-08-24 Birds Pharma Gmbh Berolina Innovative Research & Development Services Verwendung deuterierter N-[2-(5-Methoxy-1H-indol-3-yl)-ethyl]acatamide und deren pharmazeutisch verträglicher Salze sowie diese Verbindungen enthaltende Arzneimittel
WO2007024741A2 (en) 2005-08-24 2007-03-01 National Jewish Medical And Research Center Methods for treatment of thiol-containing compound deficient conditions
HUE027865T2 (en) 2005-12-01 2016-11-28 Auspex Pharmaceuticals Inc Substituted phenyl ethylamines with serotonergic and / or norepinephrine activity
US20080101995A1 (en) 2005-12-16 2008-05-01 Smiths Detection Inc. Ion mobility spectrometer having improved sample receiving device
WO2007085660A1 (en) 2006-01-30 2007-08-02 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pesticidal composition comprising indole derivates
US20090028796A1 (en) 2006-01-30 2009-01-29 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. Pesticidal composition comprising indole derivates
FI4282332T3 (fi) 2006-02-22 2024-07-08 Dexcom Inc Analyyttianturi
GB0604647D0 (en) 2006-03-08 2006-04-19 Shchepinov Mikhail Stabilized food supplements and their derivatives
GB0606147D0 (en) 2006-03-28 2006-05-10 Bioniqs Ltd Method
ES2383768T3 (es) 2006-06-28 2012-06-26 Chelsea Therapeutics Inc. Composiciones farmacéuticas que comprenden droxidopa
US20080010318A1 (en) 2006-07-05 2008-01-10 Samsung Electronics Co., Ltd. Apparatus and method for managing content stored in portable digital device
WO2008016677A2 (en) 2006-08-02 2008-02-07 Auspex Pharmaceuticals, Inc. Preparation and utility of deuterated amphetamines
DE102006040027B3 (de) 2006-08-25 2008-06-26 Christian Beer Vakuumförderer zum Transport, Ablegen und Stapeln von flächenförmigen Gegenständen
JP2010507585A (ja) 2006-10-19 2010-03-11 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換インドール
US8653106B2 (en) 2010-07-30 2014-02-18 Pisgah Laboratories, Inc. Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder
US20120183600A1 (en) 2007-01-16 2012-07-19 Chien-Hung Chen Novel composition for treating metabolic syndrome and other conditions
CN101657193A (zh) 2007-03-09 2010-02-24 切尔西治疗公司 用于治疗纤维肌痛的屈昔多巴及其药物组合物
WO2008112773A2 (en) 2007-03-12 2008-09-18 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension
WO2008140859A1 (en) 2007-03-15 2008-11-20 Auspex Pharmaceuticals, Inc. Deuterated venlafaxines and 0-desmetylvenlafaxines with serotoninergic and / or norepinephrinergic activity
CN104906669A (zh) 2007-03-30 2015-09-16 菲利普莫里斯生产公司 用于输送药剂的装置和方法
WO2008122990A1 (en) 2007-04-04 2008-10-16 Almet Corporation Limited Compacting upflow extractor and method of using it
US7687660B2 (en) 2007-04-18 2010-03-30 Teva Pharmaceutical Industries Ltd. Process for preparing intermediates of HMG-CoA reductase inhibitors
EP2514417A3 (en) 2007-05-07 2013-01-30 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
US9421266B2 (en) 2007-05-22 2016-08-23 Pisgah Laboratories, Inc. Safety of pseudoephedrine drug products
US10183001B1 (en) 2007-05-22 2019-01-22 Pisgah Laboratories, Inc. Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features
US7745665B2 (en) 2007-06-04 2010-06-29 Auspex Pharmaceuticals, Inc. Substituted phenethylamines
NO326090B1 (no) 2007-06-18 2008-09-15 Ziebel As Hylseventil
EP2020230B1 (en) 2007-08-01 2011-01-19 Laboratorios del Dr. Esteve S.A. Combination of at least two 5-HT6-Ligands
MX2010001390A (es) 2007-08-06 2010-08-02 Synosia Therapeutics Inc Métodos para el tratamiento de dependencia.
AU2014202047A1 (en) 2007-08-06 2014-05-01 Biotie Therapies, Inc. Methods for treating dependence
AU2016208412A1 (en) 2007-08-06 2016-08-18 Biotie Therapies, Inc. Methods for treating dependence
US20090043184A1 (en) 2007-08-08 2009-02-12 Edwards Lifesciences Corporation Catheter and probe for measuring analytes or other parameters
JP2010540454A (ja) 2007-09-21 2010-12-24 アカディア ファーマシューティカルズ，インコーポレーテッド ピマバンセリンと他の薬剤との併用投与
US20090093513A1 (en) 2007-10-09 2009-04-09 Hamann Mark T Method to Use Compositions Having Antidepressant Anxiolytic and Other Neurological Activity and Compositions of Matter
ES2620672T3 (es) 2008-01-09 2017-06-29 Charleston Laboratories, Inc. Comprimidos de doble capa que comprenden oxicodona y prometazina
US8329663B2 (en) 2008-01-31 2012-12-11 Paul Griffin Compositions and methods for the treatment of chronic infections
WO2009097596A1 (en) 2008-01-31 2009-08-06 Paul Griffin Compositions and methods for the treatment of chronic infections
EP2254865A1 (en) 2008-02-11 2010-12-01 Organix, Inc. Indole compounds and methods of use thereof
US20110060037A1 (en) 2008-03-12 2011-03-10 David Paul Drucker Woldbye Use of npy y5 receptor antagonists for the prevention of psycho-stimulant and opioid abuse
CA2666036C (en) 2008-05-16 2017-09-12 Chien-Hung Chen Novel compositions and methods for treating hyperproliferative diseases
EP2285362B1 (en) 2008-06-19 2017-08-09 LTS LOHMANN Therapie-Systeme AG Composition for transdermal delivery of cationic active agents
WO2010019227A1 (en) 2008-08-13 2010-02-18 George Mason Intellectual Properties, Inc. Ex vivo therapeutic screening of living bone marrow cells for multiple myeloma
US8560039B2 (en) 2008-09-19 2013-10-15 Dexcom, Inc. Particle-containing membrane and particulate electrode for analyte sensors
CA2751627A1 (en) 2009-02-06 2010-08-12 Egalet Ltd. Pharmaceutical compositions resistant to abuse
JP5550839B2 (ja) 2009-02-09 2014-07-16 株式会社 資生堂 美白剤
CN102348457A (zh) 2009-03-11 2012-02-08 奥默罗斯公司 预防和治疗成瘾的组合物和方法
JP5711724B2 (ja) 2009-04-15 2015-05-07 リサーチ・トライアングル・インスティチュート モノアミン再取り込み阻害剤
WO2010124089A2 (en) 2009-04-22 2010-10-28 Synosia Therapeutics, Inc. Methods for treating dependence
WO2010151258A1 (en) 2009-06-24 2010-12-29 The Board Of Regents Of The University Of Oklahoma Methods of treating psychological conditions
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
US20120156139A1 (en) 2009-08-31 2012-06-21 Rachel Katz-Brull Isotopically labeled neurochemical agents and uses therof for diagnosing conditions and disorders
WO2011028875A1 (en) 2009-09-03 2011-03-10 Wake Forest University Health Sciences Immunogenic conjugates for producing immune responses to drugs of abuse and methods of use
NZ599060A (en) 2009-09-16 2014-10-31 Philip Morris Products Sa Improved device and method for delivery of a medicament
US9357951B2 (en) 2009-09-30 2016-06-07 Dexcom, Inc. Transcutaneous analyte sensor
CN102115455A (zh) 2009-12-30 2011-07-06 北京德众万全药物技术开发有限公司 一种赛洛多辛关键中间体的制备方法
CA2797158A1 (en) 2010-05-10 2011-11-17 Segetis, Inc. Alkyl ketal esters as dispersants and slip agents for particulate solids, methods of manufacture, and uses thereof
AU2011252763B2 (en) 2010-05-14 2012-12-20 Charlotte L. Keating A method of treatment and diagnosis
AU2011252764B2 (en) 2010-05-14 2012-12-13 Charlotte L. Keating Neuropsychopharmacological treatment regimes for treating psychological disorders
US20120108510A1 (en) 2010-05-20 2012-05-03 Emory University Methods of improving behavioral therapies
US20110319728A1 (en) 2010-06-29 2011-12-29 Edwards Lifesciences Corporation Blood parameter sensor and flow control system, method and computer program product
CN103221070B (zh) 2010-08-30 2019-07-12 哈佛大学校长及研究员协会 用于狭窄病变和溶解血栓疗法的切变控制释放
AU2011313814B2 (en) 2010-10-07 2015-12-24 Eaglepharma Pty Ltd Combination therapy for the treatment of depression and other non-infectious diseases
US9241631B2 (en) 2010-10-27 2016-01-26 Dexcom, Inc. Continuous analyte monitor data recording device operable in a blinded mode
US20130287705A1 (en) 2010-11-03 2013-10-31 Mcmaster University Method of treating mucosal inflammation
IL298116A (en) 2010-12-22 2023-01-01 Syqe Medical Ltd Method and system for drug delivery
TW201242600A (en) 2011-01-18 2012-11-01 Targacept Inc Treatment of cognitive dysfunction in schizophrenia
CN103502817B (zh) 2011-03-28 2016-01-20 前视红外系统股份有限公司 包括药物的分析物的检测方法
US8844007B2 (en) 2011-04-08 2014-09-23 Dexcom, Inc. Systems and methods for processing and transmitting sensor data
EP2720536A4 (en) 2011-06-16 2015-04-01 Harvard College NEW AGENTS FOR COMBATING NAILS AND APPLICATIONS THEREOF
EP2551675A1 (en) 2011-07-28 2013-01-30 Chiron AS Deuterium free, stable isotope labeled 2-phenylethylamine hallucinogens and/or stimulants, methods fo their preparation and their use
US10575762B2 (en) 2011-08-05 2020-03-03 Dexcom, Inc. Systems and methods for detecting glucose level data patterns
WO2013032940A1 (en) 2011-08-26 2013-03-07 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US9730160B2 (en) 2011-09-23 2017-08-08 Dexcom, Inc. Systems and methods for processing and transmitting sensor data
EP2773409A1 (de) 2011-11-04 2014-09-10 CHV Pharma GmbH & Co. KG Inhalator sowie verfahren zum erzeugen eines aerosols
CN204576485U (zh) 2011-12-15 2015-08-19 贝克顿·迪金森公司 生理条件监视系统、生理条件传感器和生理条件仪表
GB201202223D0 (en) 2012-02-09 2012-03-28 Randox Lab Ltd Immunoassay for pyrrolidinophenones
HUE036985T2 (hu) 2012-03-23 2018-08-28 Codexis Inc Biokatalizátor és eljárások triptamin és triptamin-analógok származékainak szintetizálására
US10881339B2 (en) 2012-06-29 2021-01-05 Dexcom, Inc. Use of sensor redundancy to detect sensor failures
US8986677B2 (en) 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods
CA2880704A1 (en) 2012-08-08 2014-02-13 Presage Biosciences, Inc. Extrusion methods and devices for drug delivery
US20140066881A1 (en) 2012-08-31 2014-03-06 Zoll Medical Corporation Cardiac resuscitation methods and kits
WO2014064703A1 (en) 2012-10-28 2014-05-01 Peritech Pharma Ltd. Pharmaceutical liquid adhesive compositions for treatment of anorectal disorders
US9907503B2 (en) 2012-10-31 2018-03-06 Edwards Lifesciences Corporation Sensor systems and methods of using the same
US20140170146A1 (en) 2012-11-13 2014-06-19 Presage Biosciences, Inc. Methods for multiplexed drug evaluation
US20140242722A1 (en) 2013-02-27 2014-08-28 Medtech Detect, Llc Article and method for detection of a drug in a liquid medium
WO2014140925A2 (en) 2013-03-10 2014-09-18 Peritech Pharma Ltd. Topical compositions and methods of treatment of topical disorders
WO2014152182A1 (en) 2013-03-15 2014-09-25 President And Fellows Of Harvard College Deuterated heterocyclic inhibitors of necroptosis
EP2983473A4 (en) 2013-03-15 2016-11-23 Als Mountain Llc PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONINERGIC AGENT AND METHODS OF USING SAME
US9561183B2 (en) 2013-03-15 2017-02-07 Children's National Medical Center Prussian blue-inspired constructs for multimodal imaging and therapy
US8999992B2 (en) 2013-03-15 2015-04-07 Vm Pharma Llc Crystalline forms of tryosine kinase inhibitors and their salts
WO2014144712A1 (en) 2013-03-15 2014-09-18 Biochemics, Inc. Topical formulations and methods for drug delivery
JP6402415B2 (ja) 2013-03-15 2018-10-10 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム 選択加熱を備えたエアロゾル発生システム
RS55992B1 (sr) 2013-05-21 2017-09-29 Philip Morris Products Sa Aerosol koji sadrži distributivno sredstvo i izvor medikamenta
RU2655188C2 (ru) 2013-05-21 2018-05-24 Филип Моррис Продактс С.А. Электрически нагреваемая система подачи аэрозоля
US9511378B2 (en) 2013-10-09 2016-12-06 Georgia-Pacific Chemicals Llc Collector compositions and methods for making and using same
KR101629502B1 (ko) 2013-10-23 2016-06-10 주식회사 엘지생활건강 세정효과가 우수한 저자극 클렌징 워터 화장료 조성물
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
TW201605856A (zh) 2013-11-01 2016-02-16 艾尼納製藥公司 ５－ＨＴｃ受體促效劑
CN116170766A (zh) 2013-11-07 2023-05-26 德克斯康公司 用于分析物值的发射和连续监测的系统和方法
US9480401B2 (en) 2013-11-14 2016-11-01 Dexcom, Inc. Indicator and analytics for sensor insertion in a continuous analyte monitoring system and related methods
EP3796332B1 (en) 2013-11-14 2025-08-06 Dexcom, Inc. Devices and methods for continuous analyte monitoring
EP4309570A1 (en) 2013-12-16 2024-01-24 DexCom, Inc. Systems and methods for monitoring and managing life of a battery in an analyte sensor system worn by a user
WO2015091258A1 (en) 2013-12-19 2015-06-25 Philip Morris Products S.A. Aerosol-generating system for generating and controlling the quantity of nicotine salt particles
EP2886153A1 (de) 2013-12-20 2015-06-24 LTS LOHMANN Therapie-Systeme AG System für die transdermale Abgabe von Wirkstoff
WO2015122964A1 (en) 2014-02-11 2015-08-20 Dexcom, Inc. Packaging system for analyte sensors
WO2015127556A1 (en) 2014-02-28 2015-09-03 UNIVERSITé LAVAL Methods and uses for inducing or facilitating defecation in a patient in need thereof
WO2015127558A1 (en) 2014-02-28 2015-09-03 UNIVERSITé LAVAL Methods and uses for inducing or facilitating micturition in a patient in need thereof
CN103816150A (zh) 2014-03-14 2014-05-28 兰州理工大学 山蚂蝗生物碱单体成分的用途
WO2015164541A1 (en) 2014-04-22 2015-10-29 Presage Biosciences, Inc. Methods and devices for evaluating drug candidates
US9878138B2 (en) 2014-06-03 2018-01-30 Pop Test Abuse Deterrent Technology Llc Drug device configured for wireless communication
IL273507B2 (en) 2014-06-30 2024-06-01 Syqe Medical Ltd Methods, devices and systems for administering active substances through the lungs
US10202426B2 (en) 2014-07-30 2019-02-12 Genome Protection, Inc. Flagellin compositions and uses
WO2016033204A2 (en) 2014-08-26 2016-03-03 Echo Therapeutics, Inc. Differential biosensor system
US20160067711A1 (en) 2014-09-09 2016-03-10 The Regents Of The University Of Michigan Systems and methods for single cell isolation and analysis
US10301271B2 (en) 2014-09-17 2019-05-28 Purdue Pharma L.P. Crystalline forms of tyrosine kinase inhibitors and their salts
AU2015328459A1 (en) 2014-10-06 2017-04-20 Dexcom, Inc. System and method for data analytics and visualization
MA41557A (fr) 2015-02-18 2017-12-26 Auspex Pharmaceuticals Inc Inhibiteurs diméthoxyphényles du transporteur vésiculaire des monoamines 2
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
CN112716051B (zh) 2015-03-27 2024-04-19 菲利普莫里斯生产公司 包括破裂部分的气溶胶生成系统
CA2977592A1 (en) 2015-03-27 2016-10-06 Philip Morris Products S.A. Aerosol-generating system comprising integrated piercing element
WO2016161138A1 (en) 2015-03-31 2016-10-06 Stamets Paul Edward Antiviral activity from medicinal mushrooms and their active constituents
EP3288636A4 (en) 2015-05-01 2019-01-16 Topitech Pharma Israel Ltd. COMPOSITIONS FOR THE TREATMENT OF EPISTAXIS
WO2016187277A1 (en) 2015-05-19 2016-11-24 Joseph Robert Knight Method for isolation of alkaloids and amino acids, and compositions containing isolated alkaloids and amino acids
US20180147142A1 (en) 2015-05-19 2018-05-31 Joseph Robert Knight Method for isolation of alkaloids and amino acids, and compositions containing isolated alkaloids and amino acids
EP3346906B1 (en) 2015-09-10 2024-09-04 Dexcom, Inc. Transcutaneous analyte sensors and monitors, calibration thereof, and associated methods
WO2017044702A1 (en) 2015-09-11 2017-03-16 Pop Test LLC Therapeutic method and device
AU2016377480A1 (en) 2015-12-21 2018-04-26 Dexcom, Inc. Continuous analyte monitoring system power conservation
ES2976108T3 (es) 2015-12-30 2024-07-23 Dexcom Inc Sistemas y métodos de sensor de analito transcutáneo
CZ307719B6 (cs) 2015-12-31 2019-03-20 Vysoká škola chemicko-technologická v Praze Použití derivátu tryptaminu
US20170210704A1 (en) 2016-01-21 2017-07-27 Enlibrium Inc Deutero-phenformin derivatives
US10668030B2 (en) 2016-04-21 2020-06-02 University Of Kentucky Research Foundation Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse
WO2017189528A1 (en) 2016-04-26 2017-11-02 Ecolab USA, Inc. Corrosion inhibitor compositions and methods of using same
WO2017192397A1 (en) 2016-05-02 2017-11-09 Dexcom, Inc. System and method for providing alerts optimized for a user
DE102016014603A1 (de) 2016-06-30 2018-01-04 Thomas Herkenroth Synthetisches Ayahuasca
US20180021326A1 (en) 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
US20210069170A1 (en) 2016-07-23 2021-03-11 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
CN114711763B (zh) 2016-08-12 2026-03-24 德克斯康公司 连续葡萄糖监测的数据可视化和用户支持工具系统和方法
US20200229411A1 (en) 2016-08-21 2020-07-23 Insectergy, Llc Insect production systems and methods
US20210137137A1 (en) 2016-08-21 2021-05-13 Insectergy, Llc Insect production systems and methods
US11103499B2 (en) 2016-08-26 2021-08-31 EXCIVA (UG) (haftungsbeschränkt) Compositions and methods thereof
EP4120151A1 (en) 2016-09-09 2023-01-18 Dexcom, Inc. Method for enabling health care provider set up of a bolus calculator
WO2018057576A1 (en) 2016-09-22 2018-03-29 Auspex Pharmaceuticals, Inc. Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds
WO2018064465A1 (en) 2016-09-29 2018-04-05 The Regents Of The University Of California Compounds for increasing neural plasticity
AU2017345135B9 (en) 2016-10-18 2020-02-13 Dexcom. Inc. System and method for communication of analyte data
EP3500854B1 (en) 2016-11-09 2025-06-18 Dexcom, Inc. Systems and methods for technical support of continuous analyte monitoring and sensor systems
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
CA3139635A1 (en) 2016-12-27 2018-07-05 Dexcom, Inc. Systems and methods for patient monitoring using an hcp-specific device
NL2018190B1 (en) 2017-01-18 2018-07-26 Procare Beheer B V Psilocybin or psilocin in combination with cannabinoid
CN110418605A (zh) 2017-01-19 2019-11-05 德克斯康公司 柔性分析物传感器
EP3576755A4 (en) 2017-02-02 2020-12-02 McMaster University BICARBONATE AS A POTENTIALIZER OF ANTIMICROBIAL AGENTS
CA3052974A1 (en) * 2017-02-09 2018-08-16 CaaMTech, LLC Compositions and methods comprising a psilocybin derivative
US11974984B2 (en) 2017-02-09 2024-05-07 Caamtech, Inc. Compositions and methods comprising a combination of serotonergic drugs
WO2018145219A1 (es) 2017-02-09 2018-08-16 Serani Mostazal Jorge Composición farmaceutica para la prevención y tratamiento de las adicciones a traves de un contracondicionamiento aversivo
US20170173262A1 (en) 2017-03-01 2017-06-22 François Paul VELTZ Medical systems, devices and methods
CN108619214A (zh) 2017-03-15 2018-10-09 王慎君 一种治疗肿瘤的药物
US20200147038A1 (en) 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
MA49464A (fr) 2017-05-04 2020-04-29 Exciva GmbH Targeted drug rescue avec de nouvelles compositions, associations et procédés correspondants
WO2018204764A1 (en) 2017-05-05 2018-11-08 Camp4 Therapeutics Corporation Identification and targeted modulation of gene signaling networks
US20200061076A1 (en) 2017-05-11 2020-02-27 Ramot At Tel-Aviv University Ltd. Methods of treating leukodystrophies
US11938119B2 (en) 2017-05-31 2024-03-26 Insectergy, Llc Cannabis production systems and methods
US20190246591A1 (en) 2017-05-31 2019-08-15 Insectergy, Llc Insect and cannabis production systems and methods
US20180343812A1 (en) 2017-05-31 2018-12-06 Insectergy, Llc Cannabis farming systems and methods
EP3629899A4 (en) 2017-06-02 2021-04-21 Northwestern University Thin, soft, skin-mounted microfluidic networks for detection and analysis of targets of interest in sweat
KR102933948B1 (ko) 2017-06-23 2026-03-03 덱스콤, 인크. 경피성 분석 센서, 이를 위한 어플리케이터 및 관련 방법
EP3655380B1 (en) 2017-07-21 2021-12-22 The Florida State University Research Foundation, Inc. Photochemical separations and compositions
US20200155611A1 (en) 2017-07-23 2020-05-21 Pluristem Ltd. Methods and compositions for treating addictions
ES2924188T3 (es) 2017-09-25 2022-10-05 Small Pharma Ltd Formas sólidas de dosificación oral de derivados de ketamina
GB201715919D0 (en) 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
GB2588505B (en) 2017-10-09 2022-08-03 Compass Pathfinder Ltd Preparation of psilocybin
EP3698260A4 (en) 2017-10-19 2021-08-04 Eleusis Health Solutions US, Inc. METHODS AND SYSTEMS FOR INCREASING THE SAFETY OF AWARENESS-ENHANCING DRUG THERAPIES
DK3928687T3 (da) 2017-10-24 2024-09-30 Dexcom Inc Bærbar indretning med på forhånd forbundet analytsensor
GB201717629D0 (en) 2017-10-26 2017-12-13 Univ Oxford Innovation Ltd Treatment of unipolar depressive disorder
MA50786A (fr) 2017-10-26 2022-04-27 Blumentech S L Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
WO2019099745A1 (en) 2017-11-16 2019-05-23 CaaMTech, LLC Compositions comprising a psilocybin derivative and a cannabinoid
AU2018381331A1 (en) 2017-12-04 2020-07-23 Victoria Cogger Compositions and methods for modulating liver endothelial cell fenestrations
FI128750B (en) 2017-12-21 2020-11-30 Helsingin Yliopisto Methods for determining the therapeutic effect of fast-acting antidepressants and related individual antidepressant therapy
US20190254988A1 (en) 2018-02-16 2019-08-22 Botanical Process Solutions LLC Use of non crystalline terpene alcohols for the inhibition of crystallization of cannabinoids
CN120555529A (zh) 2018-03-08 2025-08-29 指南针探路者有限公司 生产色胺的方法
AU2019262197B2 (en) 2018-05-04 2024-12-19 Perception Neuroscience, Inc. Methods of treating substance abuse
WO2019241451A1 (en) 2018-06-12 2019-12-19 University Of Washington Modified carbazoles as therapeutic agents
CA3148256A1 (en) 2018-06-21 2019-12-26 Robert John Petcavich Method of inducing dendritic and synaptic genesis in neurodegenerative chronic diseases
WO2020023084A1 (en) 2018-07-26 2020-01-30 Applied Biology, Inc. Taar receptor agonists for the treatment of alopecia
EP3829640A4 (en) 2018-08-01 2022-05-25 McMaster University Methods for inhibiting microbe growth
WO2020024071A1 (es) 2018-08-03 2020-02-06 Universidad Del Desarrollo Composición farmacéutica para el tratamiento de la adicción a sustancias psicoactivas y/o para la prevención de las recaídas a dicha adicción
US12090145B2 (en) 2018-08-20 2024-09-17 Yale University Combination therapy for treating or preventing depression or other mood diseases
US11337937B2 (en) 2018-08-27 2022-05-24 ReJoy TARR receptor agonists for sexual dysfunction
CN108929259A (zh) 2018-08-29 2018-12-04 四川青木制药有限公司 一种制备赛洛多辛中间体的方法
WO2020053196A1 (en) 2018-09-10 2020-03-19 Universität Basel Method for the biocatalytic alkylation of a substrate
EP3626772A1 (en) 2018-09-19 2020-03-25 Borealis AG Use of a melamine based compound and a hals compound as heat stabilizer in polymers
US11672861B2 (en) 2018-10-15 2023-06-13 The George Washington University Prussian blue nanoparticles functionalized with immune signals and applications thereof
US11045454B2 (en) 2018-12-06 2021-06-29 Palo Alto Investors LP Methods of treating food allergy conditions
JP7502308B2 (ja) 2019-01-18 2024-06-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 固体投与形態を製造する方法および固体投与形態
AU2020215150B8 (en) 2019-01-30 2025-07-03 Diamond Therapeutics Inc. Methods and compositions comprising a 5HT receptor agonist for the treatment of psychological, cognitive, behavioral, and/or mood disorders
MD3927338T2 (ro) 2019-02-22 2025-03-31 Gh Res Ireland Limited Compoziții cuprinzând 5-metoxi-N,N-dimetiltriptamină (5-MeO-DMT) pentru utilizare în tratarea tulburărilor mentale
EP4353314A3 (en) 2019-02-22 2024-07-03 GH Research Ireland Limited 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating major depression
CN113784962B (zh) 2019-02-27 2025-04-25 加利福尼亚大学董事会 用于治疗脑部疾病的氮杂环庚三烯并-吲哚类和其他杂环
AU2020228289B2 (en) 2019-02-27 2026-02-05 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders
EP4219498A1 (en) 2019-03-07 2023-08-02 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations
EP3952864A4 (en) 2019-03-08 2023-05-10 The Regents of the University of California COMPOSITIONS AND METHODS FOR MODULATION OF LIPID AND STEROID METABOLISM
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
KR102920478B1 (ko) 2019-04-22 2026-01-30 덱스콤, 인크. 사전 연결식 분석물 센서
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
EP3773208A4 (en) 2019-06-04 2022-02-23 Waveform Technologies, Inc. SENSOR SIGNAL PROCESSING WITH KALMAN-BASED CALIBRATION
WO2020260917A1 (en) 2019-06-27 2020-12-30 S.L.A. Pharma Ag Topical pharmaceutical compositions comprising diltiazem
WO2020264390A2 (en) 2019-06-27 2020-12-30 Holobiome, Inc. Therapeutic compositions and methods of using serotonin modulating microbiome-based interventions to treat serotonin-related diseases or disorders
DE102019117739A1 (de) 2019-07-01 2021-01-07 Felix Blei Arylalkyamin-, Pyrrol-, Indol- und Opiatderivatkonzentrationsbestimmungsverfahren sowie Testkit unter Verwendung dieses Verfahrens
JP2022539400A (ja) 2019-07-04 2022-09-08 キャノピー グロウス コーポレイション カンナビノイド誘導体
EP3994129A4 (en) 2019-07-04 2023-01-04 Canopy Growth Corporation CANNABINOID DERIVATIVES
WO2021003467A1 (en) 2019-07-04 2021-01-07 Sw Holdings, Inc. Metered dosing compositions and methods of use of psychedelic compounds
WO2021007659A1 (en) 2019-07-12 2021-01-21 Canopy Growth Corporation Cannabinoid derivatives
WO2021007663A1 (en) 2019-07-12 2021-01-21 Canopy Growth Corporation Cannabinoid derivatives
EP3997098A4 (en) 2019-07-12 2023-10-11 Canopy Growth Corporation CANNABINOIDS DERIVATIVES
JP2022540586A (ja) 2019-07-12 2022-09-16 キャノピー グロウス コーポレイション カンナビノイド誘導体
US20220259221A1 (en) 2019-07-12 2022-08-18 Canopy Growth Corporation Cannabinoid derivatives
WO2021009374A1 (fr) 2019-07-17 2021-01-21 Universite De Reims Champagne Ardenne Composes de type liquide ionique, leurs procedes de preparation et leurs utilisations
US20210015738A1 (en) 2019-07-17 2021-01-21 Concept Matrix Solutions Oral dissolvable film containing psychedelic compound
US11766445B2 (en) 2019-07-18 2023-09-26 Concept Matrix Solutions Oral soft gel capsule containing psychedelic compound
EP4003395A4 (en) 2019-07-23 2023-07-19 Caamtech, Inc. COMPOSITIONS WITH TOAD SECRETION COMPOUNDS
WO2021016710A1 (en) 2019-07-30 2021-02-04 Tassili Life Sciences, Corp. Controlled release formulations of multiple active pharmaceutical agents, and psilocybe-derived agents in combination with cannabis-derived agents and methods for their use
US20210030787A1 (en) 2019-07-31 2021-02-04 Applied Biology, Inc. Methods for protecting hair follicles
CN112430187B (zh) 2019-08-07 2023-01-17 北京奇点势能科技有限公司 一种α,β-氘代胺类化合物、氘代药物及其制备方法
JP2022544379A (ja) 2019-08-13 2022-10-18 ザ ユニバーシティ オブ メリーランド，ボルチモア 精神障害および脳障害の処置方法
AU2020337903A1 (en) 2019-08-25 2022-03-31 Caamtech, Inc. Alkyl quarternary ammonium tryptamines and their therapeutic uses
AU2020339743A1 (en) 2019-08-30 2022-05-12 Tallinn University Of Technology Apparatus and method for determination of banned substances
WO2021052989A1 (en) 2019-09-16 2021-03-25 Danmarks Tekniske Universitet Yeast cells and methods for production of tryptophan derivatives
CN114787363A (zh) 2019-10-01 2022-07-22 恩派瑞安神经科学公司 对真菌进行遗传工程化以调节色胺表达
US11266314B2 (en) 2019-10-01 2022-03-08 Endra Life Sciences Inc. Method and system for determining a material type of an object of interest
WO2021062559A1 (en) 2019-10-02 2021-04-08 Canopy Growth Corporation Cannabinoid derivatives
EP4038058A4 (en) 2019-10-02 2023-10-25 Canopy Growth Corporation Cannabinoid derivatives
US20230295106A1 (en) 2019-10-14 2023-09-21 The Regents Of The University Of California Ergoline-like compounds for promoting neural plasticity
WO2021072530A1 (en) 2019-10-15 2021-04-22 Tassili Life Sciences, Corp. Controlled release formulations of psilocybe-derived agents and method for their use, and methods and compositions for threating mild traumatic brain injury with post traumatic stress disorder.
US20210113644A1 (en) 2019-10-16 2021-04-22 Caamtech Llc Compositions containing kratom compounds
US20210114973A1 (en) 2019-10-18 2021-04-22 First Wave Bio, Inc. Pharmaceutical formulations
US20220387339A1 (en) 2019-10-21 2022-12-08 Esolate Ltd Superfine compounds and production thereof
JP2022552903A (ja) 2019-10-28 2022-12-20 マイアミ ユニバーシティ シロシビンおよび中間体または副産物の産生方法
US11246860B2 (en) 2019-11-07 2022-02-15 Lophora ApS 5-HT2A agonists for use in treatment of depression
JP7422473B2 (ja) 2019-11-07 2024-01-26 サイビン ユーケー リミテッド 合成方法
WO2021097452A2 (en) 2019-11-15 2021-05-20 Cb Therapeutics, Inc. Biosynthetic production of psilocybin and related intermediates in recombinant organisms
CA3158059A1 (en) 2019-11-19 2021-05-27 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
US20230122510A1 (en) 2019-11-26 2023-04-20 Canopy Growth Corporation Cannabinoid derivatives
JP2023503330A (ja) 2019-11-26 2023-01-27 キャノピー グロウス コーポレイション カンナビノイド誘導体
EP4065554A4 (en) 2019-11-26 2024-01-10 Canopy Growth Corporation CANNABIGEROL DERIVATIVES AND THEIR USE AS CANNABINOID RECEPTOR MODULATORS
CA3160793A1 (en) 2019-12-04 2021-06-10 Neonmind Biosciences Inc. Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder
WO2021113958A1 (en) 2019-12-09 2021-06-17 Canopy Growth Corporation Cannabinoid derivatives
JP2023505517A (ja) 2019-12-09 2023-02-09 キャノピー グロウス コーポレイション カンナビノイド誘導体
US20230010871A1 (en) 2019-12-13 2023-01-12 Folium Labs Inc. Complexes comprising a carbohydrate polymer and an active ingredient and processes for their preparation
JP7617927B2 (ja) 2019-12-31 2025-01-20 キュア ファーマシューティカル， インコーポレイテッド 口内溶解性フィルムおよび口内溶解性フィルムを製造し、使用する方法
US20230102999A1 (en) 2020-01-10 2023-03-30 First Wave Bio, Inc. Deuterated niclosamide
PH12022551981A1 (en) 2020-02-04 2023-10-16 Mindset Pharma Inc Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
MX2022009528A (es) 2020-02-04 2022-11-14 Mindset Pharma Inc Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc.
JP2023514559A (ja) 2020-02-05 2023-04-06 イエール ユニバーシティ 頭痛障害の幻覚剤処置
WO2021159213A1 (en) 2020-02-12 2021-08-19 Neonmind Biosciences Inc. Method for producing an extract of mushroom and mushroom extract made therefrom
KR20230124103A (ko) 2020-02-18 2023-08-24 길가메쉬 파마슈티컬스, 인코포레이티드 기분 장애 치료에 사용되기 위한 특이적 트립타민
US20210267985A1 (en) 2020-02-27 2021-09-02 Gerald Horn Compositions and methods for inducing enhanced brain function
AU2021225947B2 (en) 2020-02-27 2023-05-11 Caamtech, Inc. Crystalline bis-miprocin fumarate
WO2021178579A1 (en) 2020-03-03 2021-09-10 Alte Verde Llc Cannabis treatment of insomnia, pain, and skin conditions
US11801278B2 (en) 2020-03-05 2023-10-31 Cure Pharmaceutical, Inc. Method for obtaining an extract of a plant biomass
WO2021183490A2 (en) 2020-03-09 2021-09-16 Eleusis Health Solutions Us, Inc. Methods and systems for enhancing clinical safety of psychoactive therapies
EP4118071A4 (en) 2020-03-12 2024-07-17 Bright Minds Biosciences Inc. 3-(2-(AMINOETHYL)-INDOL-4-OL DERIVATIVES, THEIR PREPARATION PROCESSES AND THEIR USE AS 5-HT2 RECEPTOR MODULATORS
US11753375B2 (en) 2020-03-19 2023-09-12 Caamtech, Inc. Crystalline psilacetin derivatives
AU2021237646B2 (en) 2020-03-19 2023-05-11 Caamtech, Inc. Crystalline norpsilocin compounds
US20230115209A1 (en) 2020-03-20 2023-04-13 Orthogonal Thinker, Inc. Psilocybin and psilocin containing compositions and methods of using and making the same
US11332441B2 (en) 2020-03-23 2022-05-17 Caamtech, Inc. Crystalline N-methyl tryptamine derivatives
US11358934B2 (en) 2020-03-23 2022-06-14 Caamtech, Inc. Crystalline forms of psilacetin
EP4125978A4 (en) 2020-04-03 2024-06-05 Turtle Bear Holdings, LLC COMPOSITIONS AND METHODS FOR MODULATING THE INFLAMMATORY RESPONSE
CA3172210A1 (en) 2020-04-07 2021-10-14 Caamtech, Inc. Crystalline 5-methoxy-n,n-diallyltryptamine compounds
AU2021254855A1 (en) 2020-04-16 2022-09-15 Pike Therapeutics, Inc. Transdermal micro-dosing delivery of psychedelics derivatives
WO2021207824A1 (en) 2020-04-17 2021-10-21 Revive Therapeutics Ltd. Use of psilocybin in the treatment of neurological brain injury and migraines
US20210322306A1 (en) 2020-04-21 2021-10-21 Cure Pharmaceutical Holding Corp. Oral dissolvable film with high load of polymeric binder
WO2021234608A1 (en) 2020-05-19 2021-11-25 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
KR20240096817A (ko) 2020-05-19 2024-06-26 사이빈 아이알엘 리미티드 중수소화된 트립타민 유도체 및 사용 방법
EP3902541B1 (en) 2020-06-02 2022-09-14 Small Pharma Ltd Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
CA3124367C (en) 2020-06-17 2022-04-26 Psilo Scientific Ltd. Aqueous extraction of psychoactive compounds from psilocybin fungus
CN116348448A (zh) 2020-07-24 2023-06-27 明德赛特制药公司 赛洛辛和赛洛西宾的可扩展合成路线
CA3186958A1 (en) 2020-07-29 2022-02-03 Judith BLUMSTOCK Extended release 5-ht receptor agonists for neurological conditions
US12122741B2 (en) 2020-08-18 2024-10-22 Cybin Irl Limited Therapeutic phenethylamine compositions and methods of use
US20220062237A1 (en) 2020-08-28 2022-03-03 Small Pharma Ltd Injectable formulation
WO2022043227A1 (en) 2020-08-28 2022-03-03 Small Pharma Ltd Injectable formulation
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
JP2023544724A (ja) 2020-10-02 2023-10-25 サイビン アイアールエル リミテッド 吸入による幻覚発動薬の送達方法および方法を実施するためのシステム
US11000534B1 (en) 2020-10-08 2021-05-11 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof
US11324762B2 (en) 2020-10-08 2022-05-10 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof
US20230405026A1 (en) 2020-11-06 2023-12-21 Mynd Life Sciences Inc. A Method of Treating Depression by Immune Modulation
IL303288A (en) 2020-12-01 2023-07-01 Small Pharma Ltd N,N-Dimethyltryptamine compounds partially or fully deuterated
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
US20240124398A1 (en) 2021-02-10 2024-04-18 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
AU2022229037A1 (en) 2021-03-02 2023-09-28 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
US20220370413A1 (en) 2021-03-06 2022-11-24 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
WO2022192097A1 (en) 2021-03-06 2022-09-15 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
WO2022195011A1 (en) * 2021-03-18 2022-09-22 Cybin Irl Limited Psilocybin analogs, salts, compositions, and methods of use
WO2022225884A1 (en) 2021-04-22 2022-10-27 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psychedelic compounds and uses thereof
IL308816A (en) 2021-05-25 2024-01-01 Atai Therapeutics Inc New n,n-dimethyltryptamine salts and crystalline salt forms
JP2024520017A (ja) 2021-05-26 2024-05-21 マインドセット ファーマ インコーポレイテッド 幻覚剤と脂肪酸との併用
WO2023036473A1 (en) 2021-09-08 2023-03-16 Cybin Irl Limited Combination drug therapies
US20250002457A1 (en) 2021-10-29 2025-01-02 Psilera Inc. N,n-dimethyltryptamine (dmt) crystalline products and methods of making the same
MX2024005955A (es) 2021-11-18 2024-06-11 Cybin Uk Ltd Formulaciones inyectables e inhalables.
WO2023107931A1 (en) 2021-12-06 2023-06-15 Terran Biosciences, Inc. Salt and solid forms of indole analogs and methods of use thereof

Also Published As

Publication number Publication date
KR20240096817A (ko) 2024-06-26
US12240813B2 (en) 2025-03-04
CN118754841A (zh) 2024-10-11
US20240067605A1 (en) 2024-02-29
EP4153564A4 (en) 2024-06-19
CN115667217A (zh) 2023-01-31
IL312785B1 (en) 2026-02-01
US20230126298A1 (en) 2023-04-27
JP2023526856A (ja) 2023-06-23
US11242318B2 (en) 2022-02-08
AU2024203974A1 (en) 2024-07-04
US11724985B2 (en) 2023-08-15
IL312785A (en) 2024-07-01
US20210363104A1 (en) 2021-11-25
US11958807B2 (en) 2024-04-16
MX2022014605A (es) 2022-12-16
US20230219889A1 (en) 2023-07-13
EP4397371A2 (en) 2024-07-10
IL325449A (en) 2026-02-01
US20220119346A1 (en) 2022-04-21
CA3177454A1 (en) 2021-11-25
US20230357147A1 (en) 2023-11-09
KR20230012501A (ko) 2023-01-26
US20230066286A1 (en) 2023-03-02
IL297492A (en) 2022-12-01
PH12022553135A1 (en) 2024-03-04
US20240270691A1 (en) 2024-08-15
JP2026031961A (ja) 2026-02-25
EP4153564A1 (en) 2023-03-29
CO2022016662A2 (es) 2022-11-29
JP2026048628A (ja) 2026-03-17
EP4397371A3 (en) 2024-10-30
US20230202979A1 (en) 2023-06-29
JP7770467B2 (ja) 2025-11-14
US20250154101A1 (en) 2025-05-15
US12291499B2 (en) 2025-05-06
US20250230128A1 (en) 2025-07-17
US12110272B2 (en) 2024-10-08
US11834410B2 (en) 2023-12-05
US11746088B2 (en) 2023-09-05
JP2024119821A (ja) 2024-09-03
US20250011282A1 (en) 2025-01-09
JP7766623B2 (ja) 2025-11-10

Similar Documents

Publication Publication Date Title
US12110272B2 (en) Deuterated tryptamine derivatives and methods of use
WO2021234608A1 (en) Deuterated tryptamine derivatives and methods of use
AU2021327136B2 (en) Therapeutic phenethylamine compositions and methods of use
HK40111458A (en) Deuterated tryptamine derivatives and methods of use

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 19 MAY 2025 TO 19 DEC 2025 IN WHICH TO PAY A CONTINUATION FEE HAS BEEN FILED

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY A CONTINUATION FEE HAS BEEN EXTENDED TO 19 DEC 2025